RCS - ValiRx PLC - ValiRx engages US investor relations firm <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

17/03/2016 07:06

RNS Number : 3712S
ValiRx PLC
17 March 2016
ValiRx Plc
("ValiRx"or "theCompany")
VALIRX ENGAGES US INVESTOR RELATIONS FIRM
London, UK, 17th March 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, announces that subsequent to the Company's establishment of a US office (announced 05.11.15), the Group has engaged Burns McClellan, a leading US-based investor relations consultancy, on an on-going basis to help create broader recognition of the Company within the US life science investor community and to encourage and facilitate greater interaction with academic, clinical, and business leaders in ValiRx's areas of oncological development.
Burns McClellan, founded over 25 years ago, is a healthcare investor relations specialist with considerable experience of supporting products and businesses in oncology with a wide range of US-based investors. During the annual J.P. Morgan healthcare conference in San Francisco in mid-January 2016, Burns McClellan conducted an institutional investor introductory programme for ValiRx, on a project basis, which the Company found beneficial and has been keen to accelerate.
Satu Vainikka, Chief Executive of ValiRx, commented:"I am pleased our relationship with Burns McClellan is developing strongly, and I look forward to the Company benefitting from enhanced engagement with US investors and other key partners in the US biotech sector."
*** ENDS ***
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive
Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.
Tel: +44 (0) 7879 458 364
tarquin.edwards@valirx.com
Mark Treharne, Corporate Development Manager
Tel: +44 (0) 7736 564 686
mark.treharne@valirx.com


Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0) 20 7148 7900
Liam Murray / Avi Robinson



Northland Capital Partners Limited (Broker)
Tel: +44 (0) 20 7382 1100
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Abigail Wayne (Broking)

About ValiRx Plc 
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed onthe Alternative Investment Market ("AIM") of the London StockExchange in October 2006.
The Company has a pipeline ofother therapeutic drugs, which are currently progressing towards clinicaltrials. The product focus is in the targeted analysis and treatment of cancer,but thetechnologies can be applied to other fields as well, such as neurologyand inflammatory diseases. It actively manages projectswithin its portfolio as a trading company. The ValiRx business model spreads the risks of life science technologydevelopment by minimizing financial exposure andrunning a set of projects todefined commercial endpoints. This maximizes returns to shareholders by adding value at the earlier stages where value increases per investment unit are thegreatest.
The Company operates through the following divisional companies:
1. ValiPharma is the therapeuticsdivision, with two embedded technologies primarily directed at the treatment ofcancers.
2. ValiFinn is the biomarkers anddiagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technology to strengthen the portfolio.
3. ValiSeek is a joint venture between ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentially other indications.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRAUBAVRNVAOARR